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1. Introduction
   Beta-lactams are a large family of antibiotics that include 
penicillin (e.g. Piperacillin), carbapenems (e.g. Meropenem) 
and cephalosporins (e.g. Cefoperazone). Meropenem is 
a carbapenem antibiotic that is active against common 
pathogens such as penicillin-sensitive, methicillin-
sensitive and anaerobes[1]. Piperacillin/tazobactam is 
a β-lactam/β-lactamase inhibitor combination with a 
broad spectrum of antibacterial activity against many 
Gram-positive and Gram-negative bacteria, including 
Pseudomonas aeruginosa[2]. Cefoperazone is a third-
generation cephalosporin antibiotic with a broad spectrum 
of activity against most Gram-positive and Gram-negative 
bacteria[3,4].
   Regarding death from cardiovascular diseases worldwide, 
oxidative stress and/or weak antioxidant defence systems 
are considered to be major players in cardiovascular 
diseases. Oxidative stress occurs when free oxygen radicals 
are produced in excessive amounts. Oxidative stress is 
characterised by an imbalance between reactive oxygen 
species and antioxidant defences[5]. Oxidative stress is 
considered to be an important factor in the initiation and 
progression of atherosclerosis and to play a role in foam 
cell formation[6]. Atherosclerosis is the primary cause of 
cardiovascular disease and coronary heart disease. It is the 
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most significant cause of global morbidity and mortality in 
the modern world[7]. The defence system that protects free 
radical damage includes enzymatic antioxidant systems. The 
most important extracellular enzyme that is involved in this 
process is the high-density lipoprotein (HDL)-associated 
human serum paraoxonase-1 (hPON1)[8].
   This enzyme catalyses the hydrolysis of organophosphates, 
aryl esters, and lactones[6,9,10]. hPON1 serves as an antioxidant 
enzyme by protecting low-density lipoproteins and HDL 
from oxidative stress, which is known to be associated 
with many vascular diseases, including atherosclerosis[11]. 
Actually, higher hPON1 activity plays a significant role in 
the prevention of atherosclerosis[12]. Epidemiological studies 
indicate that low hPON1 activity is correlated with increased 
risk of cardiovascular events and cardiovascular disease[13].
   Serum hPON1 activity is influenced by environmental 
and genetic factors and varies among individuals in all 
populations. These variations in hPON1 activity are mainly 
related to the expression of two polymorphisms located in 
the coding regions of the hPON1 gene; Q192R (Q: glutamine, 
R: arginine)[14].
   Due to the widespread prevalence of conditions it can be 
caused by reductions in hPON1 activity, its non-targeted 
inhibition is of vital importance. If any medication causes 
a reduction in hPON1 enzyme activity, many vascular 
diseases, including atherosclerosis, may occur due to 
increased oxidative stress. Indeed, further studies of the 
inhibitory effects of drugs should be performed because 
of the physiological role of hPON1. There are many studies 
regarding the effects of medications on the activity 
of hPON1. For example, Costa et al. reported that the 
cholinergic muscarinic antagonist atropine inhibited human 
serum hPON1[15]. Antibiotics, such as sodium ampicillin, 
ciprofloxacin and clindamycin sulphate have been reported 
to inhibit human serum hPON1[16].
   As mentioned, these drugs are widely used for the 
treatment of serious bacterial infections. However, it is 
extremely important to adjust the dose of these drugs in 
patients. In this study, we used a simple and rapid procedure 
to purify hPON1 from human serum and investigated the in 
vitro effects of antibacterial drugs on its enzyme activity.
2. Materials and methods
2.1. Materials
   The materials used in this study included DEAE-Sephadex 
A50, Sepharose 4B, 1-naphthylamine, paraoxon, protein 
assay reagents, and chemicals for electrophoresis and 
they were obtained from Sigma Chemical Co. All of the 
other chemicals used were of analytical grade and were 
obtained from either Sigma-Aldrich or Merck. Meropenem 
trihydrate, piperacillin sodium and cefoperazone sodium 
were obtained from local pharmaceutical manufacturing 
companies. We used a Chebios UV-vis spectrophotometer 
for the enzyme activity assays. The peristaltic pump used for 
enzyme purification was obtained from Ismatec (ISM833), the 
centrifuge machine was purchased from Hermle Labotechnic 
and the electrophoresis system was a BioRad Mini Protean 
system.
2.2. Paraoxonase activity assay
   Human serum samples were supplied from the Research 
Hospital at Ataturk University. The activity of hPON1 was 
determined at 25 °C with paraoxon (diethyl p-nitrophenyl 
phosphate) (1 mmol/L) in 50 mmol/L glycine/NaOH (pH 10.5) 
containing 1 mmol/L CaCl2. The hPON1 assay was based 
on the estimation of p-nitrophenol at 412 nm. The molar 
extinction coefficient of p-nitrophenol (ε=18.290 L/mol· 
cm at pH 10.5) was used to calculate hPON1 activity[17]. One 
enzyme unit was defined as the amount of enzyme that 
catalyses the hydrolysis of 1 µmol of substrate at 25 °C[18]. 
Assays were performed using a spectrophotometer.
2.3. Ammonium sulphate precipitation
   Human serum precipitated with 60%-80% ammonium 
sulphate was carried out in our previous studies. The 
precipitate was obtained after centrifugation at 15 000 r/min 
for 20 min and redissolved in a 100 mmol/L Na-phosphate 
buffer (pH 7.0). 
2.4. DEAE-Sephadex A50 anion exchange chromatography
   At first, the anion exchange column was equilibrated 
with a 100 mmol/L Na-phosphate buffer (pH 7.0). Then, the 
enzyme solution, which had been dialyzed in the presence 
of 1 mmol/L Na-phosphate buffer (pH 7.0) for 2 h, was loaded 
onto the DEAE-Sephadex A50 anion exchange column (3 
cm×30 cm). Later, the chromatography column was washed 
with a 100 mmol/L Na-phosphate buffer (pH 7.0), and then 
elution was carried out by an increasing linear gradient 
of (0–1.5) mol/L NaCl. The elution fractions which were 
collected were checked for enzyme activity at 412 nm. Tubes 
which displayed the same enzyme activity were combined. 
All these procedures were performed at 4 °C.
2.5. Sephadex G-200 gel filtration chromatography
   In the first process, the sephadex G-200 column (60 cm×2 
cm) was equilibrated with a 100 mmol/L Na-phosphate 
buffer (pH 7.0). The fractions obtained from the DEAE-
Sephadex A50 anion exchange column were the mixed with 
glycerol and loaded onto the gel filtration column with the 
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same buffer. Finally, the enzyme solutions were eluated 
from the Sephadex G-200 column. The protein amount (280 
nm) and enzyme activity (412 nm) for all tubes was recorded. 
The tubes showed enzyme activity were combined for other 
kinetic studies.
2.6. Protein determination
   In previous studies that were also performed in our 
laboratory, it was found spectrophotometrically at 595 nm 
according to the Bradford method to quantitative protein 
assay during the purification steps[19].
2.7.  Sodium dodecyl  sul fate  polyacrylamide gel 
electrophoresis (SDS-PAGE)
   SDS-PAGE was applied to check the enzyme that was 
purified according to the Laemmli’s procedure as in previous 
studies which were conducted in ours[20]. The obtained 
single band was photographed after electrophoresis.
2.8. In vitro studies for the drugs
   We examined the inhibitory effects of the three 
antibacterial drugs: meropenem trihydrate, piperacillin 
sodium and cefoperazone sodium. All of the compounds 
were tested in triplicate for each used concentration. The 
hPON1 activities were measured in the presence of different 
drug concentrations. Control activity was assumed to 
be 100% in the absence of an inhibitor. A percentage of 
activity vs. drug concentration graph was drawn for each 
drug. For the determination of Ki values, three different 
inhibitor concentrations were tested for each drug. In these 
experiments, paraoxone was used as a substrate at five 
different concentrations (0.15, 0.30, 0.45, 0.60, and 0.75 mmol/
L). Lineweaver-Burk curves were used for the determination 
of Ki and inhibitor type[21].
3. Results
   We purified PON1 from human serum using only three 
procedures, which are ammonium sulphate fractionation 
(60%-80%), DEAE-Sephadex anion exchange chromatography 
and Sephadex G-200 gel filtration chromatography. The 
enzyme was obtained with a specific activity of 4 060.00 EU/
mg proteins and ~295-fold with a yield of 53.9% (Table 1).
   Figure 1 shows the SDS-PAGE to determine the purity and 
molecular weight of hPON1. The molecular weight of the 
purified human serum paraoxonase was found to be 43 kDa, 
which is in agreement with other studies[22-29].
66 kDa
24 kDa
32 kDa
47.5 kDa
     B      A
Figure 1. SDS-PAGE analysis of purified hPON1. 
Lane (A) is standard proteins (kDa): Bovine serum albumin (66.000), aldolase 
(47.500), triosephosphate isomerase (32.000) and soy bean trypsin inhibitor 
(24.000). Lane (B) contains a human serum sample.
   Antibacterial drugs showed inhibition effects on 
paraoxonase activity. IC50 values for meropenem trihydrate, 
piperacillin sodium, and cefoperazone sodium were 
determined to be 0.481 mmol/L, 23.105 mmol/L, and 25.342 
mmol/L, respectively, via activity (%) vs. drug plots (Figure 
2 and Table 2). Ki constants were calculated as (0.597±0.006) 
mmol/L, (1.285±0.624) mmol/L, and (1.414±0.639) mmol/L, 
Table 1
Summary of the hPON1 purification procedure.
Purification step 
Activity 
(EU/mL)
Total volume 
(mL)
Protein 
(mg/mL)
Total protein 
(mg)
Total activity 
(EU)
Specific activity 
(EU/mg)
Yield (%)
Purification 
factor
Serum 110.70 10.00 8.00 80.00 1 100.7    13.76 100.00   1.00
Ammonium sulpate precipitation (60%-80%)   90.50   8.00 4.00 32.00   724.0    22.60   65.77   1.64
DEAE-Sephadex A50 anion exchange chromatography   50.20   6.00 0.10   0.60   301.2   502.00   41.60  36.48
Sephadex G-200 gel filtration chromatography   40.60   4.00 0.01    0.04   162.4 4 060.00   53.90 295.10
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respectively using Lineweaver–Burk curves (Figure 3 and 
Table 2). Meropenem trihydrate showed noncompetitive 
inhibition, while others inhibited in a competitive manner. 
Figure 4 shows the structural and catalytic calcium ions of 
hPON1 interact with the nitrogen and oxygen electronegative 
atoms of the functional groups in piperacillin sodium and 
Lys 192.
Table 2
IC50, Ki values and inhibition types.
Inhibitors
IC50  
(mmol/L)
Average values of  Ki 
(mmol/L)
Type of inhibition
Meropenem trihydrate   0.481 0.597±0.006 Noncompetitive
Piperacillin sodium 23.105 1.285±0.624 Competitive
Cefoperazone sodium 25.342 1.414±0.639 Competitive
 
Figure 4. The default shape binding model for the interaction between 
piperacillin sodium and the hPON1 active site. 
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4. Discussion
   Mammalian cells are protected from reactive oxygen 
species by antioxidant defense mechanisms, such as the 
activities of catalase, superoxide dismutase and glutathione 
peroxidase including PON. When the rate of the formation 
of reactive oxygen species exceeds the capacity of the 
antioxidant defense system, it has oxidative stress[30]. 
Oxidative stress is associated with cardiovascular diseases.
   hPON1 is a calcium-dependent esterase that hydrolyses 
esters, such as organophosphate and lactone[17,31], a 
glycoprotein with a molecular weight of 43-45 kDa that is 
mainly synthesised by the liver[8] and one of the proteins 
involved in the antioxidant defense mechanisms in the 
human body. There are many cleaning systems for reactive 
oxygen species, including paraoxonases, in the human 
body[32]. hPON1 protects low-density lipoprotein, HDL and 
macrophages from oxidative stress by cleaning reactive 
oxygen species during living metabolism[33,34]. Therefore, 
hPON1 prevents vascular diseases and cardiovascular 
diseases[22-24].
   According to the above information, it is clear that hPON1 
plays important physiological roles in living metabolism. 
However, there is little information regarding the 
pharmacokinetic role of this enzyme. Recently, there are 
many researches performed different types of studies on 
hPON1.
   There is a small number of studies on the interactions 
between hPON1 activity and drugs or certain chemicals[22-
29]. It is known that hPON1 has two isoforms: Q and R. These 
isoforms play a crucial role in drug metabolism and decrease 
Figure 3. Ki graphs for paraoxonase from human serum. Lineweaver-Burk plots for 5 different substrate (paraoxon) concentrations and 3 different (a) 
meropenem trihydrate, (b) piperacillin sodium, and (c) cefoperazone sodium concentrations, which were used to determine the Ki values.
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Figure 2. In vitro effect of antibacterial drugs at five different concentrations on hPON1 activity.
a: Meropenem trihydrate, b: Piperacillin sodium, c: Cefoperazone sodium.
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the risk of atherosclerosis. hPON1 enzymatic activity exhibits 
observable differences based on this polymorphism. The 
effect of this polymorphism on hPON1 activity is dependent 
on the substrate and hPON1’s activity may differ by 
ethnicity. Thus far, statins are the most widely studied 
pharmacological molecules that are used in hPON1 research. 
These studies show that various statins may have beneficial 
effects via lowering oxidative stress and increasing hPON1 
activity. It is possible that hPON1 activity might be increased 
by statins as a result of oxidative stress limitations. Statins 
appear to be generally useful to determine the hPON1 status. 
Pravastatin, simvastatin and atorvastatin have positive effect 
on PON1 activity. These drugs prevent the inactivation of 
hPON1 via their anti-oxidative properties. In addition, the 
L55M and Q192R polymorphisms in hPON1 had no effect on 
the activity of hPON1 against paraoxon and phenyl acetate 
either before or after atorvastatin treatment in an atorvastatin 
polymorphisms study[7,35-39]. Aspirin is used extensively for 
the treatment and prevention of vascular disease and is also 
known for its antioxidant effects. The hypothesis that aspirin 
may have beneficial effects on hPON1 activity was tested. 
The use of aspirin significantly increased hPON1 activity in 
patients with coronary artery disease[40]. Other drugs with 
positive impact on cardiovascular health were examined 
for their action on hPON1. The effects of valsartan and 
barnidipine were investigated and it was found that they had 
no effect on hPON1 activity[41,42].
   In an in vitro study, gentamycin sulphate and cefazolin 
sodium decreased hPON1 activity[16]. In the laboratory, 
various enzyme-drug interaction studies were conducted 
and have contributed a great deal to the literature[43,44]. 
In the laboratory studies, certain cardiovascular drugs, 
such as digoxin, metoprolol tartrate, verapamil, diltiazem, 
amiodarone, dobutamine and methylprednisolone were 
examined for their in vitro effects on hPON1. These drugs had 
a negative impact on hPON1 activity[24].
   Pharmacological studies, including enzyme-drug 
interaction analyses, are becoming increasingly vital 
important[26,27,43-48]. 
   The in vitro effects of antibacterial drugs meropenem 
trihydrate, piperacillin sodium and cefoperazone sodium on 
hPON1 activity were investigated in this study. It is crucially 
important that these antibacterial drugs are potent inhibitors 
of human serum hPON1. The compounds meropenem 
trihydrate, piperacillin sodium and cefoperazone sodium 
have inhibitory effects. For these drugs, the Ki values were 
determined by Lineweaver–Burk plots using different 
paraoxon concentrations. The drug meropenem trihydrate 
inhibited enzyme activity in a noncompetitive manner and 
both piperacillin sodium and cefoperazone sodium inhibited 
in a competitive manner. 
   The compounds piperacillin sodium and cefoperazone 
sodium behave in a similar way to paraoxon because they 
both have functional groups with the same number of 
electronegative atoms as paraoxon that interact with amino 
acids in the active site. Because piperacillin sodium and 
cefoperazone sodium have similar functional groups that 
they can compete with the substrate paraoxon by interacting 
with the active site of the enzyme. The compounds 
piperacillin sodium and cefoperazone sodium are close in Ki 
values due to similar functional groups and steric hindrance. 
It has formed a possible figure based on the studies by Harel 
et al. who have reported the crystal structure of the hPON1 
enzyme and observed amino acid residues of the active 
site[49]. In pursuit of the intended model, it was found that 
the structural and catalytic calcium ions of hPON1 interact 
with the nitrogen and oxygen electronegative atoms of the 
functional groups in piperacillin sodium and Lys 192. It is 
known that an adult human has approximately 5 L of blood. 
Accordingly, the blood concentrations of piperacillin sodium 
and cefoperazone sodium were calculated as 0.740 and 0.298 
mmol/L, respectively. These values were observed to be 
less than their respective IC50 values. However, the blood 
concentration of meropenem trihydrate was determined to be 
0.228 mmol/L, which is similar with its IC50 value. The effect 
of this observation should be clarified by in vivo studies. 
As a result, the hPON1 was purified by using three simple 
purification steps and the in vitro effects of antibacterial 
drugs on hPON1 was investigated.
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Comments 
Background
   Mammalian cells are protected from reactive oxygen 
species by antioxidant defense mechanisms, one of 
this is represented by the extracellular enzyme hPON1 
mainly synthesised by the liver. hPON1 protects low-
density lipoprotein, HDL, and macrophages from oxidative 
stress by cleaning reactive oxygen species during living 
metabolism.Therefore, hPON1 prevents vascular diseases and 
cardiovascular diseases. 
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Research frontiers
   The cutting-edge of this research is to present a rapid 
tool to evaluate the anti-oxidant activity of antibiotics, in 
cardiovascular diseases acting on human serum hPON1, 
the most important extracellular enzyme that is involved in 
antioxidant activity acting in cardiovascular diseases.
Related reports
   Few studies have shown interactions between drugs 
and hPON1. In an in vitro study, gentamycin sulphate and 
cefazolin sodium decreased hPON1 activity as certain 
cardiovascular drugs. In fact in their laboratory studies, 
certain cardiovascular drugs, such as digoxin, metoprolol 
tartrate, verapamil, diltiazem, amiodarone, dobutamine and 
methylprednisolone, were examined for their in vitro effects 
on hPON1. These drugs had a negative impact on hPON1 
activity.
Innovations and breakthroughs
   The innovation in this paper is the use of a rapid and 
easy tool to test drugs with anti-oxidant activity on hPON1 
pxidative enzyme.
  
Applications
   From literature, few studies showed that certain classes 
of antibiotics act on hPON1 reducing its activity as several 
cardiovascular drugs. In this paper they deepened the 
knowledge on the activity of antibiotics in cardiovascular 
diseases studying the effects of meropenem trihydrate, 
piperacillin sodium, and cefoperazone sodium.
Peer review
   The research proposed in this article has a meaningful 
potential presenting two key concepts: highlighting how 
antibiotics can be studied for their cardiovascular effects 
and anti-oxidant activity and developing a rapid assay to 
test anti-oxidant activity.
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